Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132),Journal of Medicinal Chemistry

当前位置： X-MOL 学术 › J. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2022-02-18 , DOI: 10.1021/acs.jmedchem.1c02110
Yan Shi ₁ , Ying Wang ₁ , Wei Meng ₁ , Robert P Brigance ₁ , Denis E Ryono ₁ , Scott Bolton ₁ , Hao Zhang ₁ , Sean Chen ₁ , Rebecca Smirk ₁ , Shiwei Tao ₁ , Joseph A Tino ₂ , Kristin N Williams ₁ , Richard Sulsky ₁ , Laura Nielsen ₁ , Bruce Ellsworth ₁ , Michael K Y Wong ₃ , Jung-Hui Sun ₃ , Leslie W Leith ₃ , Dawn Sun ₃ , Dauh-Rurng Wu ₃ , Anuradha Gupta ₄ , Richard Rampulla ₃ , Arvind Mathur ₃ , Bang-Chi Chen ₃ , Aiying Wang ₅ , Helen G Fuentes-Catanio ₅ , Lori Kunselman ₅ , Michael Cap ₅ , Jacob Zalaznick ₅ , Xiaohui Ma ₅ , Heng Liu ₅ , Joseph R Taylor ₅ , Rachel Zebo ₅ , Beverly Jones ₅ , Stephen Kalinowski ₅ , Joann Swartz ₅ , Ada Staal ₅ , Kevin O'Malley ₆ , Lisa Kopcho ₆ , Jodi K Muckelbauer ₇ , Stanley R Krystek ₇ , Steven A Spronk ₇ , Jovita Marcinkeviciene ₆ , Gerry Everlof ₈ , Xue-Qing Chen ₈ , Carrie Xu ₈ , Yi-Xin Li ₈ , Robert A Langish ₈ , Yanou Yang ₈ , Qi Wang ₈ , Kamelia Behnia ₈ , Aberra Fura ₈ , Evan B Janovitz ₉ , Nicola Pannacciulli ₁₀ , Steven Griffen ₁₀ , Bradley A Zinker ₅ , John Krupinski ₅ , Mark Kirby ₅ , Jean Whaley ₅ , Robert Zahler ₁ , Joel C Barrish ₁ , Jeffrey A Robl ₁ , Peter T W Cheng ₁

Affiliation

Fibrosis Chemistry, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Cancer Resistance and Neuroscience Chemistry, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Department of Discovery Synthesis, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Department of Discovery Synthesis, Small Molecule Drug Discovery, Research & Early Development, Biocon-Bristol Myers Squibb Research & Development Center, Bangalore 560099, India.
Cardiovascular & Fibrosis Discovery Biology, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Lead Evaluation, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Molecular Structure & Design, Small Molecule Drug Discovery, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Pharmaceutics, Preclinical Candidate Optimization, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Drug Development and Preclinical Studies, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Clinical Pharmacology, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.

Glucokinase (GK) is a key regulator of glucose homeostasis, and its small-molecule activators represent a promising opportunity for the treatment of type 2 diabetes. Several GK activators have been advanced into clinical trials and have demonstrated promising efficacy; however, hypoglycemia represents a key risk for this mechanism. In an effort to mitigate this hypoglycemia risk while maintaining the efficacy of the GK mechanism, we have investigated a series of amino heteroaryl phosphonate benzamides as ‘‘partial” GK activators. The structure–activity relationship studies starting from a “full GK activator” 11, which culminated in the discovery of the “partial GK activator” 31 (BMS-820132), are discussed. The synthesis and in vitro and in vivo preclinical pharmacology profiles of 31 and its pharmacokinetics (PK) are described. Based on its promising in vivo efficacy and preclinical ADME and safety profiles, 31 was advanced into human clinical trials.

中文翻译：

发现部分葡萄糖激酶激活剂临床候选物：二乙基（(3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)甲基）膦酸酯（BMS-820132）

葡萄糖激酶 (GK) 是葡萄糖稳态的关键调节剂，其小分子激活剂代表了治疗 2 型糖尿病的有希望的机会。几种 GK 激活剂已进入临床试验并显示出有希望的疗效；然而，低血糖是这种机制的主要风险。为了减轻这种低血糖风险，同时保持 GK 机制的功效，我们研究了一系列氨基杂芳基膦酸酯苯甲酰胺作为“部分”GK 激活剂。讨论了从“全 GK 激活剂” 11开始的结构-活性关系研究，最终发现了“部分 GK 激活剂” 31 (BMS-820132)。合成和体外和体内描述了31的临床前药理学概况及其药代动力学 (PK)。基于其有希望的体内疗效和临床前 ADME 和安全性，31已进入人体临床试验。

更新日期：2022-02-18

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南